Market research giants merge to form GfK-TNS

Share this article:

GfK and TNS are moving forward on a "merger of equals," to be completed 4Q, 2008, pending board approvals.  The announcement was made on June 3. 

Hajo Riesenbeck, currently chairman of GfK's supervisor board, will become GfK-TNS chairman of the board. Donald Brydon, currently TNS chairman of the board, will become the senior independent director. David Lowden, chief executive of TNS, will retain his title, as will Christian Weller von Ahlefeld, chief financial officer at GfK.

GfK-TNS will operate in 111 countries, with a global head office in London, and a German head office in Nürnberg, according to the announcement.

Upon full acceptance of the deal, TNS shareholders and GfK shareholders will each hold approximately 50% of the share capital of GfK-TNS following completion of the merger.

The company statement emphasizes GfK's strength in Central and Eastern Europe, complemented by TNS's coverage of Asia Pacific, among other benefits, such as “specific expertise in key client sectors combined with industry-leading research expertise.”

The proposed merger was first announced in April.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...